Quarterly report pursuant to Section 13 or 15(d)

ORGANIZATION AND BUSINESS (Details)

v3.21.2
ORGANIZATION AND BUSINESS (Details)
9 Months Ended
Oct. 25, 2021
USD ($)
Sep. 30, 2021
USD ($)
Product
Facility
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Organization and Business [Abstract]        
Number of Plasma Collection Facilities Under Development | Facility   9    
Number of FDA-Licensed Plasma Collection Facilities | Facility   3    
Number of FDA approved product | Product   3    
Working capital   $ 142,400,000    
Cash and cash equivalents   34,400,000    
Cumulative losses   (395,463,301)   $ (340,465,103)
Proceeds from issuance of common stock, net of offering expenses   $ 67,315,677 $ 99,343,207  
Subsequent Event [Member]        
Organization and Business [Abstract]        
Proceeds from issuance of common stock, net of offering expenses $ 53,900,000      
Public Offering [Member] | Subsequent Event [Member]        
Organization and Business [Abstract]        
Proceeds from issuance of common stock, net of offering expenses $ 53,900,000      
Minimum [Member]        
Organization and Business [Abstract]        
Production cycle from procurement of raw materials to release of finished product   7 months    
Maximum [Member]        
Organization and Business [Abstract]        
Production cycle from procurement of raw materials to release of finished product   12 months